Yet, it has been clearly shown that enhancement of CXCL10 in an in vivo set-up increases anti-tumor immunity and could be effectively used for cancer immunotherapy either as monotherapy, or in combined therapy with immune checkpoint inhibitors (78). The gene discussed is CXCL10; the disease is neoplasm.